Inclusion Criteria:  Female or male patients aged 18 years and older infected with the SARS-CoV-2 virus. Patients that have COVID-19 symptoms within 72 hours and have a positive PCR test result. Patients in a stable clinical condition and referred as outpatient for COVID-19 infection. Patients who sign the informed consent before the any study procedures.  Exclusion Criteria:  Patients who have required hospitalization. Patients who have required intensive care. Patients who do not sign the informed consent. Any condition that in the investigator's judgement might interfere with study procedures or the ability of the patient to adhere to and complete the study. Patients who have been participating in any other clinical trial. Severe liver failure (Child Pugh score ≥ C, transaminase>5 times the upper limit of normal (ULN). Severe renal failure (GFR ≤30 mL/min/1.73 m2) or continuous dialysis (hemodialysis, peritoneal dialysis) or continuous renal replacement therapy. Severe cardiac disease. History of hypersensitivity to either ribavirin/favipiravir. Pregnant or breast-feeding. Patients who cannot use appropriate contraceptive method during and after the study. Patients who are treated with any other treatment agent for COVID-19 in the last 90 days. Patients who had COVID-19 vaccination. Patients who had ribavirin/favipiravir for any reason in the past 72 hours.